Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Mutations associated with familial melanoma impair p16INK4 function


Cell division is controlled by a series of positive and negative regulators which act at sequential points throughout the cell cycle. Disturbance of these checks could contribute to cancer by allowing excessive cell proliferation. The point in G1 at which cells irrevocably commit to DMA synthesis is controlled by protein complexes consisting of cyclin-dependent kinases (CDK4 or CDK6) and cyclins (D1, D2 or D3). These complexes are inhibited by low molecular weight proteins, such as p16INK4 (refs 1,2), p15INK4B (ref. 3) and p18 (ref. 4). Deletion or mutation of these CDK-inhibitors could lead to unchecked cell growth, suggesting that members of the p16INK4family may be tumour suppressor genes. The recent detection of p16INK4 (MTS1) mutations in familial melanoma kindreds5,6, many human tumour cell lines7,8, and primary tumours9,10 is consistent with this idea. Previously, we described eight germline p16INK4 substitutions in 18 familial melanoma kindreds5. Genetic analyses suggested that five mutations predisposed carriers to melanoma, whereas two missense mutations had no phenotypic effect. We now describe biochemical analyses of the missense germline mutations and a single somatic mutation detected in these families. Only the melanoma-predisposing mutants were impaired in their ability to inhibit the catalytic activity of the cyclin D1/CDK4 and cyclin D1/CDK6 complexes in vitro. Our data provide a biochemical rationale for the hypothesis that carriers of certain p16INK4 mutations are at increased risk of developing melanoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others


  1. Serrano, M., Hannon, G.J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704–707 (1993).

    Article  CAS  PubMed  Google Scholar 

  2. Serrano, M., G—mez-Lahoz, E., DePinho, R., Beach, D. & Bar-Sagi, D. Inhibition of Ras-induced proliferation and cellular transformation by p16INK4. Science 267, 249–252 (1995).

    Article  CAS  PubMed  Google Scholar 

  3. Hannon, G.J. & Beach, D. p15INK4B is a potential effector of TGF-_-induced cell cycle arrest. Nature 371, 257–261 (1994).

    Article  CAS  PubMed  Google Scholar 

  4. Guan, K-L. et al. Growth suppression of p18, a P16INK4/MTS1 and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Devel. 8, 2939–2952 (1994).

    Article  CAS  PubMed  Google Scholar 

  5. Hussussian, C.J. et al. Germline p16 mutations in familialmelanoma. Nature Genet. 8, 15–21 (1994).

    Article  CAS  PubMed  Google Scholar 

  6. Kamb, A. et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 22–26 (1994).

    Article  CAS  Google Scholar 

  7. Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440 (1994).

    Article  CAS  PubMed  Google Scholar 

  8. Nobori, T., Miura, K., Wu, D.J., Lois, A., Takabayashi, K. & Carson, D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753–756 (1994).

    Article  CAS  PubMed  Google Scholar 

  9. Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8, 27–32 (1994).

    Article  CAS  PubMed  Google Scholar 

  10. Mori, T., Miura, K., Aoki, T., Nishihara, T., Mori, S. & Nakamura, M. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54, 3396–3397 (1994).

    CAS  PubMed  Google Scholar 

  11. Goldstein, A.M., Dracopoli, N.C., Engelstein, M., Fraser, M.C., Clark, W.H. Jr. & Tucker, M.A. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. hum. Genet. 54, 489–496 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. MacGeoch, C. et al. Genetic heterogeneity in familial malignant melanoma. Hum. molec. Genet. 3, 2195–2200 (1994).

    Article  CAS  PubMed  Google Scholar 

  13. Bale, S.J. et al. Mapping of the gene for hereditary cutaneous malignant melanoma. New Eng. J. Med. 320, 1367–1372 (1989).

    Article  CAS  PubMed  Google Scholar 

  14. Goldstein, A.M. et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1 p and evidence for genetic heterogeneity. Am. J. hum. Genet. 52, 537–550 (1993).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Cannon-Albright, L.A. et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13–p22. Science 258, 1148–1152 (1992).

    Article  CAS  PubMed  Google Scholar 

  16. Nancarrow, D.J. et al. Confirmation of chromosome 9p linkage in familial melanoma. Am. J. hum. Genet. 53, 936–942 (1993).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Cormack, B. in Current Protocols in Molecular Biology, (eds Ausubel, P.M.) (John Wiley & Sons, New York, 1991).

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Ranade, K., Hussussian, C., Sikorski, R. et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10, 114–116 (1995).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing